Kinetic efficiency: The missing metric for enhancing compound quality?

Drug Discovery Today

Volumn 16, Issue 21-22, 2011, Pages 910-913

  Holdgate, Geoffrey A ^a   Gill, Adrian L ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; AMISULPRIDE; AMOXAPINE; ARIPIPRAZOLE; CANDESARTAN; CHLORPROMAZINE; CLOZAPINE; DOMPERIDONE; HALOPERIDOL; IRBESARTAN; LIGAND; LOSARTAN; LOXAPINE; OLANZAPINE; OLMESARTAN; PALIPERIDONE; PERLAPINE; QUETIAPINE; RACLOPRIDE; REMOXIPRIDE; RISPERIDONE; TELMISARTAN; VALSARTAN;

CHEMICAL REACTION KINETICS; DECISION MAKING; DISSOCIATION; DRUG INDICATION; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; HYPERTENSION; LIGAND BINDING; MEASUREMENT; METHODOLOGY; PHYSICAL CHEMISTRY; QUALITY CONTROL; REVIEW; SCHIZOPHRENIA;

EID: 80255131239     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.09.006     Document Type: Short Survey

References (24)

1. W. Huber, and F. Mueller Biomolecular interaction analysis in drug discovery using surface plasmon resonance technology Curr. Pharm. Des. 12 2006 3999 4021 (Pubitemid 44669759)
2. J. Concepcion Label-free detection of biomolecular interactions using BioLayer interferometry for kinetic characterization Comb. Chem. High Throughput Screen. 12 2009 791 800
3. M.A. Cooper Label-free screening of bio-molecular interactions Anal. Bioanal. Chem. 377 2003 834 842 (Pubitemid 40882959)
4. S. Ricard-Blum Dual polarization interferometry characterization of carbohydrate-protein interactions Anal. Biochem. 352 2006 252 259 (Pubitemid 44294418)
5. D.J. Bornhop Free-solution, label-free molecular interactions studied by back-scattering interferometry Science 17 2007 1732 1736 (Pubitemid 47461834)
6. D.C. Swinney The role of binding kinetics in therapeutically useful drug action Curr. Opin. Drug Discov. Dev. 12 2009 31 39
7. R. Zhang, and F. Monsma The importance of drug-target residence time Curr. Opin. Drug Discov. Dev. 12 2009 488 496
8. H. Lu, and P.J. Tonge Drug-target residence time: critical information for lead optimization Curr. Opin. Chem. Biol. 14 2010 467 474
9. R. Zhang, and F. Monsma Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs Expert Opin. Drug Discov. 5 2010 1023 1029
10. R.A. Copeland Drug-target residence times and its implications for lead optimization Nat. Rev. Drug Discov. 5 2007 730 739 (Pubitemid 44323700)
11. C. Lipinski Drug like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 44 2000 235 249 (Pubitemid 32239479)
12. P.D. Leeson, and B. Springthorpe The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discov. 6 2007 881 890 (Pubitemid 350042396)
13. A.L. Hopkins Ligand efficiency: a useful metric for lead selection Drug Discov. Today 9 2004 430 431 (Pubitemid 38510559)
14. J.E. Ladbury Enthalpic efficiency and the role of thermodynamic data in drug development: possibility or a pipeline dream! Eur. Pharmaceut. Rev. 6 2007 http://www.europeanpharmaceuticalreview.com
15. M.J. Waring Lipophilicity in drug discovery Expert Opin. Drug Discov. 5 2010 235 248
16. R.A. Copeland The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety Expert Opin. Drug Discov. 5 2010 305 310
17. L. Neumann Fragment-based lead generation: identification of seed fragments by a highly efficient fragment screening technology J. Comput.-Aided Mol. Des. 23 2009 501 511
18. C. Reynolds Ligand binding efficiency: trends, physical basis and implications J. Med. Chem. 51 2008 2432 2438 (Pubitemid 351628504)
19. 2 receptor Bioorg. Med. Chem. 19 2011 2231 2241
20. G.G. Ferenczy, and G.M. Keserũ Thermodynamics guided lead discovery and optimization Drug Discov. Today 21-22 2010 919 932
21. I. Van Liefde, and G. Vauquelin Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism Mol. Cell Endocrinol. 302 2008 237 243
22. P. Seeman An update of fast-off dopamine D2 atypical antipsychotics Am. J. Psychiatry 162 2005 1984 1985 (Pubitemid 41428639)
23. B. Fuchs Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man J. Pharm. Pharmacol. 52 2000 1075 1083
24. M.T. Le Molecular characterization of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor Br. J. Pharmacol. 151 2007 952 962 (Pubitemid 47195538)